CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seaside Therapeutics announced that data on its clinical candidate, STX209, was presented today in an oral presentation at the 42nd Autism Society National Conference in Orlando, FL, by Barbara Rathmell, M.D., Senior Medical Director at Seaside Therapeutics. The talk, titled “Potential Pharmaceutical Treatments for Improving Social Function in ASD,” described positive data from an open-label Phase 2a study of STX209 conducted in patients with autism spectrum disorders (ASD). STX209 is a selective gamma-amino butyric acid type B (GABA-B) receptor agonist being studied for the treatment of ASD and fragile X syndrome (FXS).
